home All News open_in_new Full Article

Studienerfolg: Biontech erreicht Meilenstein in der Krebsforschung

Das Mainzer Unternehmen meldet einen bedeutenden Fortschritt in der Krebsforschung. Das Medikament BNT323 zeigt vielversprechende Ergebnisse bei fortgeschrittenem Brustkrebs.


today 18 h. ago attach_file Society

attach_file Society
attach_file Society
attach_file Society
attach_file Society
attach_file Society
attach_file Society
attach_file Society
attach_file Society
attach_file Society
attach_file Society
attach_file Society
attach_file Society
attach_file Society
attach_file Society
attach_file Society
attach_file Politics
attach_file Politics
attach_file Society
attach_file Society
attach_file Society


ID: 907904934
Add Watch Country

arrow_drop_down